MANNKIND CORPORATION
MNKD US56400P7069
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 36% | 18% | -30% | 64% | -2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Tross Stuart A SR OFF |
5.34 USD |
47,000 Sold |
250,980 USD |
16/09/2025 | 16/09/2025 |
| Binder Steven B. |
3.94 USD |
75,367 Sold |
296,946 USD |
15/07/2025 | 16/07/2025 |
| Thomson David EX VP |
3.94 USD |
7,466 Sold |
29,416 USD |
15/07/2025 | 16/07/2025 |
| Binder Steven B. |
4.00 USD |
64,085 Sold |
256,340 USD |
10/06/2025 | 10/06/2025 |
| Binder Steven B. |
4.00 USD |
64,085 Sold |
256,340 USD |
10/06/2025 | 10/06/2025 |
| Binder Steven B. |
4.40 USD |
12,078 Sold |
53,143 USD |
19/05/2025 | 20/05/2025 |
| Thomson David EX VP |
4.41 USD |
2,345 Sold |
10,341 USD |
19/05/2025 | 20/05/2025 |
| Binder Steven B. |
4.40 USD |
12,078 Sold |
53,143 USD |
19/05/2025 | 20/05/2025 |
| Thomson David EX VP |
4.41 USD |
2,345 Sold |
10,341 USD |
19/05/2025 | 20/05/2025 |
| Thomson David EX VP |
4.68 USD |
32,179 Sold |
150,598 USD |
10/05/2025 | 13/05/2025 |